Corrections:

Lucia Longhitano¹, Carlo Castruccio Castracani¹, Daniele Tibullo¹, Roberto Avola¹, Maria Viola¹, Giuliano Russo¹, Orazio Prezzavento⁴, Agostino Marrazzo⁴, Emanuele Amata⁴, Michele Reibaldi², Antonio Longo², Andrea Russo², Nunziatina Laura Parrinello³ and Giovanni Li Volti^1,5

¹Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
²Department of Ophthalmology, University of Catania, Catania, Italy
³Regional Reference Center for Rare Diseases, Clinical Division of Hematology and Transplantation, PO Ferrarotto Hospital, Azienda Ospedaliera-Universitaria Policlinico-Vittorio Emanuele, Via Citelli, Catania, Italy
⁴Department of Drug Sciences, University of Catania, Catania, Italy
⁵Euromediterranean Institute of Science and Technology, Palermo, Italy

Published: March 14, 2024

Copyright: © 2024 Longhitano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4A, the 1st plate image in the 10 μM column is an accidental duplicate of the 2nd plate image in that same column. The corrected Figure 4, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:91099–91111. DOI: https://doi.org/10.18632/oncotarget.19556

Figure 4: Colony formation capacity following treatments with (+)-Pentazocine, Haloperidol and Haloperidol metabolite II. (A) Images are representative of four separate experiments and (B) number of colonies were manually counted and presented as the mean ± SD of four independent experiments. (*p < 0.01 vs. control).